Evidence map›Paper›PMID 36384958›Full record

ArticleMolecular pharmacology2023

Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling Predicted by Three-Dimensional Missense Tolerance Ratio Analysis.

Carolina Montañez-Miranda, Riley E Perszyk, Nicholas H Harbin, Jennifer Okalova, Suneela Ramineni, Stephen F Traynelis, John R Hepler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. GNature communications · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Carolina Montañez-MirandaDepartment of Pharmacology and Chemical Biology (C.M.-M., R.E.P., N.H.H., S.R., S.F.T., J.R.H.) and Aflac Cancer and Blood Disorders Center, Department of Pediatrics (J.O.), Emory University School of Medicine, Atlanta, Georgia.ORCID 0000-0002-5913-1959
Riley E PerszykDepartment of Pharmacology and Chemical Biology (C.M.-M., R.E.P., N.H.H., S.R., S.F.T., J.R.H.) and Aflac Cancer and Blood Disorders Center, Department of Pediatrics (J.O.), Emory University School of Medicine, Atlanta, Georgia.ORCID 0000-0001-8283-7709
Nicholas H HarbinDepartment of Pharmacology and Chemical Biology (C.M.-M., R.E.P., N.H.H., S.R., S.F.T., J.R.H.) and Aflac Cancer and Blood Disorders Center, Department of Pediatrics (J.O.), Emory University School of Medicine, Atlanta, Georgia.
Jennifer OkalovaDepartment of Pharmacology and Chemical Biology (C.M.-M., R.E.P., N.H.H., S.R., S.F.T., J.R.H.) and Aflac Cancer and Blood Disorders Center, Department of Pediatrics (J.O.), Emory University School of Medicine, Atlanta, Georgia.
Suneela RamineniDepartment of Pharmacology and Chemical Biology (C.M.-M., R.E.P., N.H.H., S.R., S.F.T., J.R.H.) and Aflac Cancer and Blood Disorders Center, Department of Pediatrics (J.O.), Emory University School of Medicine, Atlanta, Georgia.
Stephen F TraynelisDepartment of Pharmacology and Chemical Biology (C.M.-M., R.E.P., N.H.H., S.R., S.F.T., J.R.H.) and Aflac Cancer and Blood Disorders Center, Department of Pediatrics (J.O.), Emory University School of Medicine, Atlanta, Georgia.ORCID 0000-0002-3750-9615
John R HeplerDepartment of Pharmacology and Chemical Biology (C.M.-M., R.E.P., N.H.H., S.R., S.F.T., J.R.H.) and Aflac Cancer and Blood Disorders Center, Department of Pediatrics (J.O.), Emory University School of Medicine, Atlanta, Georgia Jhepler@emory.edu.ORCID 0000-0002-1090-2919
Emory University · US

Funding

Structure and Function of the G-alpha-i1:RGS14:H-Ras signaling complexR01NS037112 · NINDS · EMORY UNIVERSITY · PI HEPLER, JOHN R · 1998 to 2023
$7.2M
Glutamate receptors and human neurological diseaseR35NS111619 · NINDS · EMORY UNIVERSITY · PI Stephen F Traynelis · 2019 to 2026
$6.6M
RGS14 Regulation of Hormone-sensitive NPT2A-mediated Phosphate TransportR01GM140632 · NIGMS · EMORY UNIVERSITY · PI FRIEDMAN, PETER A, HEPLER, JOHN R · 2021 to 2024
$1.8M
RGS proteins as novel integrators of G protein and MAPK signalingR56NS037112 · NINDS · EMORY UNIVERSITY · PI HEPLER, JOHN R · 2009 to 2009
$374k
NIGMS NIH HHS R01 GM140632NINDS NIH HHS R01 NS037112NINDS NIH HHS R35 NS111619NINDS NIH HHS R56 NS037112
6 · The paper itself

Abstract

Regulators of G protein signaling (RGS) proteins modulate G protein-coupled receptor (GPCR) signaling by acting as negative regulators of G proteins. Genetic variants in RGS proteins are associated with many diseases, including cancers, although the impact of these mutations on protein function is uncertain. Here we analyze the RGS domains of 15 RGS protein family members using a novel bioinformatic tool that measures the missense tolerance ratio (MTR) using a three-dimensional (3D) structure (3DMTR). Subsequent permutation analysis can define the protein regions that are most significantly intolerant (

Indexed as

NeoplasmsRGS ProteinsGTP-Binding ProteinsHumansMutationSignal TransductionGTP-Binding ProteinsRGS10 protein, humanRGS Proteins

Identifiers

PMID36384958
PMCPMC10955721
OpenAlexW4309246254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.